RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT00576680 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neuroendocrine Tumor

Interventions

DRUG: RAD001
DRUG: Temozolomide

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]